SCHEMBL29652391

SCHEMBL29652391

c1cc2cc(-c3cnc(N4CCCC4)nc3)cnc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 6/20 0.56
AXL P30530 2/20 0.56
PIK3CA P42336 2/20 0.55
PIK3CD O00329 1/20 0.55
PIK3CB P42338 1/20 0.55
PIK3CG P48736 1/20 0.55
RIPK1 Q13546 4/20 0.54
ROCK2 O75116 3/20 0.48
PLK4 O00444 3/20 0.48
MAP4K4 O95819 3/20 0.48
ROS1 P08922 3/20 0.48
MARK3 P27448 3/20 0.48
FLT4 P35916 3/20 0.48
KDR P35968 3/20 0.48
CLK2 P49760 3/20 0.48
CSNK1G2 P78368 3/20 0.48
ROCK1 Q13464 3/20 0.48
MINK1 Q8N4C8 3/20 0.48
AURKB Q96GD4 3/20 0.48
PRKD2 Q9BZL6 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652339 0.89 CDK8 (0.54) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL29652420 0.87 PLK4 (0.58) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL28502063 0.87 CDK8 (0.52) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL29652315 0.86 RIPK1 (0.52) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL4831501 0.80 CDK8 (0.81) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL30597879 0.80 RIPK1 (0.49) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL12821760 0.79 PIK3CA (0.51) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL18860575 0.78 KDM4E (0.48) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL18860531 0.77 KDM4E (0.47) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL9277647 0.76 OGA (0.50) PIK3CAROCK2ROCK1CDK2STK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195516-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2025-06-19 US disclosed
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 US disclosed
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2022-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor MAP3K20, PRKACA, MAP3K13 CDK8 69/4885AXL 1476/4885PIK3CA 80/4885
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 CDK8 69/4885AXL 1476/4885PIK3CA 80/4885
US-20250195516-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 CDK8 69/4885AXL 1476/4885PIK3CA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.